Physiomics PLC Issue of Options (8674J)
April 29 2022 - 5:00AM
UK Regulatory
TIDMPYC
RNS Number : 8674J
Physiomics PLC
29 April 2022
29 April 2022
Physiomics plc
("Physiomics") or (the "Company")
Issue of Options
The Company considers that the award of options linked to the
Company's performance is critical to the incentivisation of its
employees and to ensure that there is alignment between management
and shareholders.
To this end, the Company today confirms that it has agreed to
issue 850,000 share options (the "Options") over ordinary shares of
0.4p each in the Company ("Ordinary Shares") to its non-director
employees, under the Company's existing Enterprise Management
Initiative Employee Share Option Scheme (the "Scheme") as detailed
in this announcement.
Each Option issued will be exercisable at a price of 4.38p,
being the greater of (i) the average closing price for the three
dealing days immediately preceding the date of grant; and (ii) the
closing price on the dealing day immediately prior to the date of
grant, as prescribed in the terms of the Schemes.
The Options vest equally over a three-year period and can be
exercised within 10 years of the date of grant.
Following this issue, there will be no change in the number of
Options or in the holdings of ordinary shares of directors in the
Company.
The total number of shares in issue remains 97,424,778 Ordinary
Shares with voting rights attached (one vote per Ordinary Share).
There are no Ordinary Shares held in treasury. This total voting
rights figure may be used by shareholders as the denominator for
the calculations by which they will determine whether they are
required to notify their interests in, or a change to their
interest in, Physiomics under the Disclosure and Transparency
Rules.
Enquiries:
Physiomics plc
Dr Jim Millen, CEO
+44 (0)1865 784 980
Hybridan LLP (broker)
Claire Louise Noyce
+44 (0) 203 764 2341
Strand Hanson Ltd (NOMAD)
James Dance & James Bellman
+44 (0)20 7409 3494
Notes to Editor
About Physiomics
Physiomics plc (AIM: PYC) is an oncology consultancy using
mathematical models to support the development of cancer treatment
regimens and personalised medicine solutions. The Company's Virtual
Tumour(TM) technology uses computer modelling to predict the
effects of cancer drugs and treatments to improve the success rate
of drug discovery and development projects while reducing time and
cost. The predictive capability of Physiomics' technologies have
been confirmed by over 80 projects, involving over 40 targets and
70 drugs, and has worked with clients such as Merck KGaA, Astellas,
Merck & Co and Bicycle Therapeutics.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
IOEILMPTMTATMTT
(END) Dow Jones Newswires
April 29, 2022 05:00 ET (09:00 GMT)
Physiomics (LSE:PYC)
Historical Stock Chart
From Apr 2024 to May 2024
Physiomics (LSE:PYC)
Historical Stock Chart
From May 2023 to May 2024